BNB Plus Secures European Patent for Linea™ RNAP Technology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 18 2026
0mins
Should l Buy BNBX?
Source: Newsfilter
- Patent Milestone: BNB Plus Corp.'s subsidiary LineaRx has been granted a European patent by the EPO for its chemically modified RNA polymerase (RNAP), marking a significant advancement in building the company's global intellectual property portfolio and enhancing its competitive edge in the European biotherapeutics market.
- Market Validation Plans: The patent is set to be validated in key European markets by 2040, aiming to provide mRNA manufacturers with solutions for producing higher-quality mRNA, thereby driving the company's commercialization potential in the rapidly growing biopharmaceutical sector.
- Acquisition Background: BNB Plus acquired the technology underlying Linea RNAP through its acquisition of Spindle Bio in July 2023, enriching the company's technological assets and laying the groundwork for future product development.
- Efficiency Improvement: As a core component of the Linea IVT platform, Linea RNAP simplifies the mRNA production workflow and reduces double-stranded RNA contamination, enabling manufacturers to produce high-quality mRNA more efficiently, further solidifying the company's market position in the biopharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BNBX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BNBX
About BNBX
BNB Plus Corp., formerly Applied DNA Sciences, Inc., is a digital asset treasury (DAT) company that has adopted BNB, the native cryptocurrency of the Binance blockchain ecosystem, as its primary reserve asset. Its segments include digital asset treasury, therapeutic deoxyribonucleic acid (DNA) production services, DNA tagging and security products and services. Its digital asset treasury segment is engaged in managing digital assets. Its therapeutic DNA production services segment is engaged in nucleic-acid production solutions for the biopharmaceutical and diagnostics industries, including LineaDNA, LineaRNAP and LineaIVT. Its DNA tagging and security products and services segment is engaged in the manufacture and detection of DNA for industrial supply chains and security services. Its subsidiary LineaRx, Inc., is engaged in commercializing nucleic acid production solutions for the biopharmaceutical and diagnostics markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Coinbase Shares Rise on Security Talks with Anthropic
- Stock Surge: Coinbase shares rose over 4% to $192 in morning trading, driven by Chief Security Officer Philip Martin's announcement of talks with Anthropic regarding its Mythos AI model, reflecting market confidence in the company's security strategy.
- Security Demand Communication: Martin highlighted that Mythos tools could expedite testing for cyber threats and defenses; however, while major banks like Goldman Sachs have early access, crypto firms have yet to be included in the initial rollout, indicating a pressing need for advanced security technologies in the industry.
- Analyst Target Upgrade: Piper Sandler raised Coinbase's price target from $150 to $180, maintaining a cautious outlook on year-over-year comparisons for Q2 2026, yet noted that the ongoing Iran War could provide strong market support, showcasing analysts' optimism about the company's future performance.
- Positive Market Sentiment: On Stocktwits, retail sentiment around Coinbase remained in the 'bullish' zone, indicating investor confidence in the company's prospects, especially as global market volatility increases, which could drive higher trading volumes.
See More
BNB Plus Secures European Patent for Linea™ RNAP Technology
- Patent Milestone: BNB Plus Corp.'s subsidiary LineaRx has been granted a European patent by the EPO for its chemically modified RNA polymerase (RNAP), marking a significant advancement in building the company's global intellectual property portfolio and enhancing its competitive edge in the European biotherapeutics market.
- Market Validation Plans: The patent is set to be validated in key European markets by 2040, aiming to provide mRNA manufacturers with solutions for producing higher-quality mRNA, thereby driving the company's commercialization potential in the rapidly growing biopharmaceutical sector.
- Acquisition Background: BNB Plus acquired the technology underlying Linea RNAP through its acquisition of Spindle Bio in July 2023, enriching the company's technological assets and laying the groundwork for future product development.
- Efficiency Improvement: As a core component of the Linea IVT platform, Linea RNAP simplifies the mRNA production workflow and reduces double-stranded RNA contamination, enabling manufacturers to produce high-quality mRNA more efficiently, further solidifying the company's market position in the biopharmaceutical industry.
See More
Virtual Investor Conferences Showcase Digital Asset Conference Presentations
- Online Access to Presentations: Virtual Investor Conferences announced that presentations from the Digital Asset Virtual Conference held on January 27th are now available for online viewing 24/7 for 90 days, enhancing investor access to critical information.
- 1x1 Meeting Requests: Selected companies are accepting management meeting requests through January 30th, providing investors with direct engagement opportunities with executives, thereby improving investor relations management effectiveness.
- Investor Engagement Platform: The conference serves as an interactive forum for publicly traded companies to present directly to investors, increasing investor engagement and optimizing communication efficiency between companies and investors, which promotes market activity.
- Global Investor Network: The event attracted a global network of retail and institutional investors, showcasing the reach of Virtual Investor Conferences and further driving investment opportunities in the digital asset space.
See More
Virtual Investor Conferences Showcase Digital Asset Conference Presentations
- Presentation Availability: Virtual Investor Conferences announced that presentations from the Digital Asset Virtual Conference held on January 27 are now available online for 90 days, enhancing investor access to critical information.
- 1x1 Meeting Requests: Selected companies are accepting 1x1 management meeting requests until January 30, providing investors with direct engagement opportunities with company executives, thereby improving investor relations management.
- Investor Engagement Platform: The conference offers a real-time investor engagement solution designed to provide publicly traded companies with more efficient access to investors, facilitating direct communication between companies and their stakeholders.
- Global Investor Network: By enhancing presentations with dynamic video content, the conference connects a global network of retail and institutional investors, further modernizing investor communications and engagement strategies.
See More
FuelCell Energy Files for $200 Million Stock Offering, Shares Drop 8.9%
- Stock Offering: FuelCell Energy announced an amended sales agreement to increase the total amount of shares available for sale to $200 million, which led to an 8.9% drop in share price to $7.23 on Wednesday, indicating a negative market reaction to the dilution of shares.
- Market Reaction: The announcement of the stock offering raised investor concerns, as the significant drop in share price could impact the company's future fundraising capabilities and market confidence, particularly in the current economic climate where investors are sensitive to equity dilution.
- Funding Purpose: FuelCell Energy plans to use the proceeds from this offering to support its R&D and operational expenditures, and while the stock faces short-term pressure, successful fundraising could provide the necessary capital to drive technological innovation and market expansion in the long run.
- Industry Impact: In the context of increasing competition in the hydrogen and fuel cell industry, FuelCell Energy's stock offering may affect its reputation among investors, especially as the effectiveness of its financing strategy will directly influence its market position compared to other competitors.
See More
BNB Plus Corp. Ships Record $390K LineaDNA Order, Anticipates More Deliveries
- Historic Shipment: BNB Plus Corp. successfully manufactured and shipped its largest single LineaDNA order valued at over $390,000, showcasing the company's robust production capabilities and market demand in the cancer diagnostics sector.
- Future Delivery Expectations: Under the previously announced supply agreement, the company anticipates fulfilling additional multi-gram deliveries in the first half of 2026, which will not only further solidify its position in the biopharmaceutical market but also drive future revenue growth.
- Technological Advantage: The LineaDNA platform leverages the company's deep expertise in large-scale PCR to produce high-fidelity DNA that is rapidly scalable and amenable to chemical modification, enhancing the company's competitiveness in the fiercely competitive biotech industry.
- Market Responsiveness: CEO Clay Shorrock emphasized that despite facing market challenges, the team continues to deliver at a high level, demonstrating the company's resilience and commitment to its partners in uncertain environments.
See More
Coinbase Shares Rise on Security Talks with Anthropic
- Stock Surge: Coinbase shares rose over 4% to $192 in morning trading, driven by Chief Security Officer Philip Martin's announcement of talks with Anthropic regarding its Mythos AI model, reflecting market confidence in the company's security strategy.
- Security Demand Communication: Martin highlighted that Mythos tools could expedite testing for cyber threats and defenses; however, while major banks like Goldman Sachs have early access, crypto firms have yet to be included in the initial rollout, indicating a pressing need for advanced security technologies in the industry.
- Analyst Target Upgrade: Piper Sandler raised Coinbase's price target from $150 to $180, maintaining a cautious outlook on year-over-year comparisons for Q2 2026, yet noted that the ongoing Iran War could provide strong market support, showcasing analysts' optimism about the company's future performance.
- Positive Market Sentiment: On Stocktwits, retail sentiment around Coinbase remained in the 'bullish' zone, indicating investor confidence in the company's prospects, especially as global market volatility increases, which could drive higher trading volumes.
See More
BNB Plus Secures European Patent for Linea™ RNAP Technology
- Patent Milestone: BNB Plus Corp.'s subsidiary LineaRx has been granted a European patent by the EPO for its chemically modified RNA polymerase (RNAP), marking a significant advancement in building the company's global intellectual property portfolio and enhancing its competitive edge in the European biotherapeutics market.
- Market Validation Plans: The patent is set to be validated in key European markets by 2040, aiming to provide mRNA manufacturers with solutions for producing higher-quality mRNA, thereby driving the company's commercialization potential in the rapidly growing biopharmaceutical sector.
- Acquisition Background: BNB Plus acquired the technology underlying Linea RNAP through its acquisition of Spindle Bio in July 2023, enriching the company's technological assets and laying the groundwork for future product development.
- Efficiency Improvement: As a core component of the Linea IVT platform, Linea RNAP simplifies the mRNA production workflow and reduces double-stranded RNA contamination, enabling manufacturers to produce high-quality mRNA more efficiently, further solidifying the company's market position in the biopharmaceutical industry.
See More
Virtual Investor Conferences Showcase Digital Asset Conference Presentations
- Online Access to Presentations: Virtual Investor Conferences announced that presentations from the Digital Asset Virtual Conference held on January 27th are now available for online viewing 24/7 for 90 days, enhancing investor access to critical information.
- 1x1 Meeting Requests: Selected companies are accepting management meeting requests through January 30th, providing investors with direct engagement opportunities with executives, thereby improving investor relations management effectiveness.
- Investor Engagement Platform: The conference serves as an interactive forum for publicly traded companies to present directly to investors, increasing investor engagement and optimizing communication efficiency between companies and investors, which promotes market activity.
- Global Investor Network: The event attracted a global network of retail and institutional investors, showcasing the reach of Virtual Investor Conferences and further driving investment opportunities in the digital asset space.
See More
Virtual Investor Conferences Showcase Digital Asset Conference Presentations
- Presentation Availability: Virtual Investor Conferences announced that presentations from the Digital Asset Virtual Conference held on January 27 are now available online for 90 days, enhancing investor access to critical information.
- 1x1 Meeting Requests: Selected companies are accepting 1x1 management meeting requests until January 30, providing investors with direct engagement opportunities with company executives, thereby improving investor relations management.
- Investor Engagement Platform: The conference offers a real-time investor engagement solution designed to provide publicly traded companies with more efficient access to investors, facilitating direct communication between companies and their stakeholders.
- Global Investor Network: By enhancing presentations with dynamic video content, the conference connects a global network of retail and institutional investors, further modernizing investor communications and engagement strategies.
See More
FuelCell Energy Files for $200 Million Stock Offering, Shares Drop 8.9%
- Stock Offering: FuelCell Energy announced an amended sales agreement to increase the total amount of shares available for sale to $200 million, which led to an 8.9% drop in share price to $7.23 on Wednesday, indicating a negative market reaction to the dilution of shares.
- Market Reaction: The announcement of the stock offering raised investor concerns, as the significant drop in share price could impact the company's future fundraising capabilities and market confidence, particularly in the current economic climate where investors are sensitive to equity dilution.
- Funding Purpose: FuelCell Energy plans to use the proceeds from this offering to support its R&D and operational expenditures, and while the stock faces short-term pressure, successful fundraising could provide the necessary capital to drive technological innovation and market expansion in the long run.
- Industry Impact: In the context of increasing competition in the hydrogen and fuel cell industry, FuelCell Energy's stock offering may affect its reputation among investors, especially as the effectiveness of its financing strategy will directly influence its market position compared to other competitors.
See More
BNB Plus Corp. Ships Record $390K LineaDNA Order, Anticipates More Deliveries
- Historic Shipment: BNB Plus Corp. successfully manufactured and shipped its largest single LineaDNA order valued at over $390,000, showcasing the company's robust production capabilities and market demand in the cancer diagnostics sector.
- Future Delivery Expectations: Under the previously announced supply agreement, the company anticipates fulfilling additional multi-gram deliveries in the first half of 2026, which will not only further solidify its position in the biopharmaceutical market but also drive future revenue growth.
- Technological Advantage: The LineaDNA platform leverages the company's deep expertise in large-scale PCR to produce high-fidelity DNA that is rapidly scalable and amenable to chemical modification, enhancing the company's competitiveness in the fiercely competitive biotech industry.
- Market Responsiveness: CEO Clay Shorrock emphasized that despite facing market challenges, the team continues to deliver at a high level, demonstrating the company's resilience and commitment to its partners in uncertain environments.
See More
